Eradigm Consulting
Natalie Poole is the current Finance Director at Eradigm Consulting. Natalie has previously worked as a Group Financial Controller, Leisure and Capital at Soho House & Co from July 2016 to November 2019. Prior to that, they were an Interim Group Capital Accountant at the same company from April 2016 to July 2016. Natalie has also worked as a Senior Manager, Compensation and Benefits at Jimmy Choo from December 2013 to January 2015, and as a Finance Manager at the same company from December 2010 to December 2013. Additionally, they have worked as a Senior Management Accountant at Travelzest plc from October 2009 to December 2010, and as a Management Accountant at London Clubs International from November 2007 to May 2009. Natalie began their career as an Accountant at H.J Hatfield & Sons from May 2002 to July 2004, before taking on the role of Assistant Management Accountant at Harvey Nichols from July 2004 to November 2006.
Natalie Poole holds a BA (Hons) in Accounting & Finance from the University of Brighton.
They are on a team with Gala Farooq - Consultant, Ilaria Coppola - Senior Consultant, and David Mcbay - Consultant. Natalie Poole reports to Patrick Romano, Co-Founder & Partner.
This person is not in any offices
Eradigm Consulting
2 followers
Eradigm works with select biopharmaceutical companies to develop a deeper and more nuanced understanding of their markets. We focus on informing and shaping high impact strategies for your product or portfolio, whatever its stage in the clinical or commercial life-cycle. Our core expertise is built on decades of experience in the pharmaceutical sector, giving us the ability to deliver value to our clients at the intersection of three key industry dynamics: the ever increasing value imperative, shrinking sources of true competitive advantage and cutting edge therapeutic innovation. Our founding team’s experience spans more than 30 years both leading and supporting the development and commercialisation of some of the world’s most lucrative and innovative biopharmaceutical products.